Trevi Therapeutics, Inc. (TRVI)

NASDAQ

$12.60

$-0.33

(-2.59%)

Previous Close: ⁦$12.94⁩

Market Closed

Trevi Therapeutics, Inc. (TRVI) Live Price Chart

Last updated: ⁦2026-10-24 13:36:40⁩. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.

Summary

Trevi Therapeutics, Inc. (TRVI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $12.60, with a market capitalization of $1.84B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.82 to $20.22. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$1.84B
Open	$12.74
Day's High	$20.22
Day's Low	$0.46
Previous Close	$12.94
Volume	1.11M
Average Volume	1.96M
P/E Ratio	--
52-Week High	$20.22
52-Week Low	$9.82
Dividend Yield	--
Earnings Date	--

Trevi Therapeutics, Inc. (TRVI) Latest Closing Stock Price

Trevi Therapeutics, Inc. (TRVI) last closed at $12.94 as of 2026-10-23 23:31:00, unchanged from the previous close of $12.94.

During the latest regular trading session, TRVI traded between $0.46 and $20.22, with a volume of 1.11M shares. The closing price was near the middle and near the lower end of its 52-week range.

Trevi Therapeutics, Inc. (TRVI) 7-Day Stock Price Change

Over the past seven days, Trevi Therapeutics, Inc. (TRVI) moved from $12.11 to $12.60, representing a gain of 4.05% ($0.49).

The stock traded between $11.70 and $14.88 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.

The average daily volume was 1.87 million shares, down versus the previous seven-day period, indicating lower trading activity.

TRVI 52-Week Price Position

Position in Range: 26.7%

52W Low$9.82

52W High$20.22

TRVI is currently trading at $12.60, placing it 26.7% of the way from its 52-week low of $9.82 to its 52-week high of $20.22. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Trevi Therapeutics, Inc. (TRVI)?

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Trevi Therapeutics, Inc. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	34
Exchange	NASDAQ
Company Website	https://www.trevitherapeutics.com

How to Buy Trevi Therapeutics, Inc. (TRVI) Stock on MEXC

Eligible investors can buy real shares of Trevi Therapeutics, Inc. (TRVI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for TRVI and Place Your Order

Open the RealStocks trading page and search for TRVI. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Trevi Therapeutics, Inc. (TRVI) stock price today?

Trevi Therapeutics, Inc. (TRVI) is currently trading at $ 12.60, down 2.62% ($0.34) from the previous close of $ 12.94. Intraday prices update in real time during regular trading hours.

2.Is TRVI stock going up or down today?

As of 2026-10-23 23:31:00, TRVI is trading at $ 12.60, down 2.62% ($0.34) from its previous close of $ 12.94. The stock has traded between $ 0.46 and $ 20.22 during today’s regular session. Past price movements do not guarantee future results.

3.What is TRVI pre-market price?

As of 2026-10-23 23:31:00, TRVI is trading at $ 13.05 in pre-market trading, up 0.81% ($0.11) from the previous close of $ 12.94. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is TRVI after-hours price?

As of 2026-10-23 23:31:00, TRVI is trading at $ 12.61 in after-hours trading, down 2.59% ($0.33) from the regular-session close of $ 12.94. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is TRVI stock trading now?

TRVI trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does TRVI sit relative to its 52-week high and low?

Over the past 52 weeks, TRVI has traded between a low of $ 9.82 and a high of $ 20.22. At $ 12.60, the stock is positioned 26.7% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Trevi Therapeutics, Inc. in?

Trevi Therapeutics, Inc. (TRVI) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Trevi Therapeutics, Inc.'s market capitalization and where is it listed?

Trevi Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalization of $ 1.84B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is TRVI valued in terms of P/E ratio and EPS?

TRVI trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -0.36. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Trevi Therapeutics, Inc. pay a dividend?

Trevi Therapeutics, Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.